Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.

Barroilhet L, Yang J, Hasselblatt K, Paranal RM, Ng SK, Rauh-Hain JA, Welch WR, Bradner JE, Berkowitz RS, Ng SW.

Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.

PMID:
22945647
[PubMed - indexed for MEDLINE]
2.

BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.

May T, Yang J, Shoni M, Liu S, He H, Gali R, Ng SK, Crum C, Berkowitz RS, Ng SW.

Neoplasia. 2013 Jun;15(6):600-8.

PMID:
23730208
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Interaction of ZEB and histone deacetylase with the PLDLS-binding cleft region of monomeric C-terminal binding protein 2.

Zhao LJ, Kuppuswamy M, Vijayalingam S, Chinnadurai G.

BMC Mol Biol. 2009 Sep 15;10:89. doi: 10.1186/1471-2199-10-89.

PMID:
19754958
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC, Blaydes JP.

Biol Cell. 2010 Jan;103(1):1-19. doi: 10.1042/BC20100067.

PMID:
20964627
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.

Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T.

Int J Cancer. 2010 Sep 1;127(6):1332-46. doi: 10.1002/ijc.25151.

PMID:
20049841
[PubMed - indexed for MEDLINE]
6.

Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC.

de Jong E, Winkel P, Poelstra K, Prakash J.

PLoS One. 2011;6(9):e25192. doi: 10.1371/journal.pone.0025192. Epub 2011 Sep 21.

PMID:
21957481
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.

J Inorg Biochem. 2012 Aug;113:94-101. doi: 10.1016/j.jinorgbio.2012.04.007. Epub 2012 Apr 27.

PMID:
22717676
[PubMed - indexed for MEDLINE]
8.

Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.

Kwiecińska P, Wróbel A, Taubøll E, Gregoraszczuk EŁ.

Toxicol Lett. 2014 Jan 13;224(2):225-32. doi: 10.1016/j.toxlet.2013.10.035. Epub 2013 Nov 5.

PMID:
24200999
[PubMed - indexed for MEDLINE]
9.

Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.

Borutinskaite VV, Magnusson KE, Navakauskiene R.

Mol Biol Rep. 2012 Dec;39(12):10179-86. doi: 10.1007/s11033-012-1892-5. Epub 2012 Sep 26.

PMID:
23007576
[PubMed - indexed for MEDLINE]
10.

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.

Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL.

Br J Pharmacol. 2008 Feb;153(4):657-68. Epub 2007 Dec 3.

PMID:
18059320
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.

Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM.

Cancer Biol Ther. 2007 May;6(5):795-801. Epub 2007 Feb 14.

PMID:
17387270
[PubMed - indexed for MEDLINE]
Free Article
12.

HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).

Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O.

Pancreatology. 2012 Mar-Apr;12(2):146-55. doi: 10.1016/j.pan.2012.02.013. Epub 2012 Feb 25.

PMID:
22487525
[PubMed - indexed for MEDLINE]
13.

Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B.

Gastroenterology. 2012 Sep;143(3):811-20.e1-15. doi: 10.1053/j.gastro.2012.05.033. Epub 2012 May 26.

PMID:
22641068
[PubMed - indexed for MEDLINE]
14.

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H.

Cancer Res. 2011 Jul 1;71(13):4412-22. doi: 10.1158/0008-5472.CAN-10-4111. Epub 2011 May 13.

PMID:
21571862
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.

Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, Chen X.

Oncogene. 2013 Jan 31;32(5):599-609. doi: 10.1038/onc.2012.81. Epub 2012 Mar 5.

PMID:
22391568
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Oh ET, Park MT, Choi BH, Ro S, Choi EK, Jeong SY, Park HJ.

Invest New Drugs. 2012 Apr;30(2):435-42. doi: 10.1007/s10637-010-9568-2. Epub 2010 Oct 27.

PMID:
20978925
[PubMed - indexed for MEDLINE]
17.

Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling.

Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA.

Stem Cells. 2012 Nov;30(11):2366-77. doi: 10.1002/stem.1219.

PMID:
22961641
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, Zou W.

Immunity. 2013 Sep 19;39(3):611-21. doi: 10.1016/j.immuni.2013.08.025. Epub 2013 Sep 5.

PMID:
24012420
[PubMed - indexed for MEDLINE]
20.

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.

BMC Med Genomics. 2009 Nov 30;2:67. doi: 10.1186/1755-8794-2-67.

PMID:
19948057
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk